Providence, RINCT06998069Now EnrollingIRB Ready

Head and Neck Neoplasms Clinical Trial in Providence, RI

Access cutting-edge head and neck neoplasms treatment through this phase 3 clinical trial at a research site in Providence. Study-provided care at no cost to qualified participants.

Sponsored by Brown University

Quick Self-Assessment

See if you qualify for this Providence location

Preparing your pre-screening questions…

Expert Care in Providence

Access head and neck neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related head and neck neoplasms treatment provided free

Apply for This Providence Location

Check if you qualify for this head and neck neoplasms clinical trial in Providence, RI

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Providence

    Convenient for RI residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Providence site if eligible
  4. 4Begin participation

About This Head and Neck Neoplasms Study in Providence

This is a study conducted in patients with a diagnosis of stage IB-IVA squamous cell carcinoma of the head and neck. Patients will have a comprehensive geriatric assessment (CGA) as part of standard assessments. The patients classified as frail, with a CGA score of 3-5, will then be treated with a novel reduced intensity regimen. The regimen will be tailored based on the programmed cell death ligand 1 combined positive score (PD-L1 CPS) and will involve 4 cycles of systemic chemotherapy and/or immunotherapy followed by radiation treatment.

Sponsor: Brown University

Who Can Participate

Inclusion Criteria

Patients must have the following
Pathology confirmed squamous cell carcinoma of the head and neck (unknown primary is excluded).
Confirmed stage of disease between IB and IVA, based on imaging studies.
CGA score of 3-5
Evaluation by medical oncology and radiation oncology.
Patients in the experimental group must be eligible for systemic treatment with chemoimmunotherapy followed by radiation treatment as determined by the geriatric oncology team.
Age ≥ 65 years.
ECOG performance status ≤ 2
Adequate organ and marrow function as defined below: Absolute neutrophil count ≥1.0 x 109/L Platelets \>100,000/mm3 Total bilirubin \<1.5 x ULN Aspartate aminotransferase (ast/sgot) \<3 x ULN Alanine aminotransferase (alt/sgpt) \<3 x ULN Creatinine clearance ≥ 40 mL/min as determined by Cockcroft Gault (using actual body weight) or \<1.5 x Upper limit of normal Males: CLcr (mL/min) = "\[140 - age (years)\] × weight (kg)" /"72 × serum creatinine (mg/dL)" Females: (CLcr (mL/min) = "\[140 - age (years)\] × weight (kg)" /"72 × serum creatinine (mg/dL)" × 0.85
Patients receiving pembrolizumab must meet standard institutional criteria for immunotherapy including no history of severe autoimmune disease.
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
Patients with metastases, including treated brain metastases, are not eligible for enrollment.
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better.
Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria

Patients who have previously received systemic chemoimmunotherapy for H/N cancer.
Patients with uncontrolled intercurrent illness.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Providence?

Yes, this clinical trial (NCT06998069) has an active research site in Providence, RI that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Head and Neck Neoplasms Treatment Options in Providence, RI

If you're searching for head and neck neoplasms treatment options in Providence, RI, this clinical trial (NCT06998069) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Providence research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced head and neck neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all head and neck neoplasms clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Providence, RI

See all alzheimers disease clinical trials recruiting in Providence — not just this study.

Browse Alzheimers Disease Trials in Providence →

Browse More Trials by Condition

Alzheimers Disease TrialsMultiple Sclerosis TrialsAnkylosing Spondylitis TrialsAtopic Dermatitis TrialsAll Conditions →

Ready to Join in Providence?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Providence, RI